Petros Pharmaceuticals, Inc. (PTPI)
D
Pipeline Grade
Financial Position (from SEC Filings)
$4.4M
Cash & Equivalents
$0.8M
Quarterly Burn Rate
17 mo
Est. Cash Runway
$0M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (6)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06119581 | A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR... | PHASE3 | Recruiting | 1,264 |
| NCT04628767 | Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary ... | PHASE3 | Recruiting | 131 |
| NCT06524544 | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatmen... | PHASE3 | Recruiting | 320 |
| NCT05384626 | A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Ac... | PHASE2 | Recruiting | 840 |
| NCT03093116 | A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement... | PHASE2 | Recruiting | 500 |
| NCT05168566 | Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | PHASE2 | Recruiting | 99 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.